Moreover, different studies have revealed that GLP-1 agonists reduced the circulating levels of pro-inflammatory C-reactive protein (CRP) [18] and interleukin (IL)-6 [19] in patients with T2D. This evidence concerns the gene GCG and type 2 diabetes mellitus.